Compass Therapeutics Quarterly Balance Sheet
NASDAQ: CMPXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Compass Therapeutics financial position
As of Sep 30, 2026, Compass Therapeutics reported total assets of $174.5 million, down 24.5% from a year earlier against total liabilities of $31.9 million. Shareholders' equity stood at $142.6 million, or 81.7% of assets. The company held $41.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 6.79, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Compass Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q3 20262026-09-30 | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 41.47M | 35.45M | 55.17M | 30.64M | 46.21M | 22.86M | 41.05M | 43.48M | 19.40M | 19.40M | 43.48M | 24.23M |
| Short-Term Investments | 121.59M | 144.43M | 139.52M | 178.26M | 173.68M | 78.09M | 71.59M | 83.24M | 98.60M | 126.82M | 132.58M | 128.23M |
| Total Current Assets | 165.50M | 180.89M | 195.69M | 209.82M | 221.12M | 106.19M | 124.14M | 132.75M | 141.14M | 153.55M | 158.61M | 153.88M |
| Property, Plant & Equipment | 402.00K | 324.00K | 169.00K | 102.00K | 119.00K | 131.00K | 102.00K | 353.00K | 493.00K | 592.00K | 744.00K | 898.00K |
| Total Assets | 174.50M | 190.17M | 205.17M | 219.59M | 231.26M | 116.70M | 131.45M | 140.40M | 149.15M | 155.61M | 161.14M | 156.88M |
| Accounts Payable | 6.32M | 2.91M | 906.00K | 1.58M | 3.10M | 2.60M | 1.58M | 2.25M | 960.00K | 1.19M | 854.00K | 4.09M |
| Total Current Liabilities | 24.37M | 16.13M | 10.28M | 13.97M | 12.41M | 13.86M | 14.90M | 8.87M | 4.43M | 9.51M | 3.89M | 7.80M |
| Total Liabilities | 31.93M | 24.12M | 18.70M | 22.80M | 21.65M | 23.49M | 21.17M | 15.17M | 10.75M | 9.51M | 4.08M | 8.34M |
| Shareholders' Equity | 142.57M | 166.05M | 186.47M | 196.79M | 209.61M | 93.21M | 110.28M | 125.23M | 138.40M | 146.10M | 157.06M | 148.54M |
| Retained Earnings | -501.81M | -474.64M | -449.49M | -431.17M | -415.46M | -401.20M | -381.32M | -364.68M | -349.65M | -339.17M | -326.10M | -315.31M |
| Net Cash (Debt) | 163.06M | 179.88M | 194.69M | 208.91M | 219.90M | 100.95M | 112.64M | 126.72M | 118.00M | 146.23M | 176.06M | 152.46M |
| Shares Outstanding | 180.09M | 180.09M | 180.09M | 178.32M | 177.57M | 138.28M | 138.28M | 137.82M | 137.59M | 137.59M | 137.59M | 127.67M |
This table shows 12 quarterly periods of Compass Therapeutics's balance sheet, from Q3 2026 back to Q4 2023, across 15 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow CMPX's reporting calendar. What is a balance sheet?